ID

33360

Description

A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.; ODM derived from: https://clinicaltrials.gov/show/NCT01290718

Lien

https://clinicaltrials.gov/show/NCT01290718

Mots-clés

  1. 06/12/2018 06/12/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

6 décembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT01290718

Eligibility Breast Cancer NCT01290718

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female patients, 18-65 years of age
Description

Gender | Age

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
histologically confirmed her2-positive breast cancer with measurable lesions (according to recist criteria)
Description

HER2-positive carcinoma of breast | Measurable lesion

Type de données

boolean

Alias
UMLS CUI [1]
C1960398
UMLS CUI [2]
C1513041
metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with herceptin and taxanes
Description

Neoplasm Metastasis | Status post First line treatment | Recurrent disease Post Neoadjuvant Therapy | Recurrent disease Post Adjuvant therapy | Herceptin | Taxanes

Type de données

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C1708063
UMLS CUI [3,1]
C0277556
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C0600558
UMLS CUI [4,1]
C0277556
UMLS CUI [4,2]
C0687676
UMLS CUI [4,3]
C0677850
UMLS CUI [5]
C0338204
UMLS CUI [6]
C0796419
ecog performance status 0-2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
cns metastases which are not well controlled
Description

CNS metastases Poorly controlled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C3853134
simultaneous treatment with sorivudine
Description

sorivudine

Type de données

boolean

Alias
UMLS CUI [1]
C0207628
history of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix
Description

Cancer Other | Exception Basal cell carcinoma Cured | Exception Carcinoma in situ of uterine cervix Cured

Type de données

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1880198
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
UMLS CUI [3,3]
C1880198
pregnant or lactating women
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147

Similar models

Eligibility Breast Cancer NCT01290718

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
female patients, 18-65 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast | Measurable lesion
Item
histologically confirmed her2-positive breast cancer with measurable lesions (according to recist criteria)
boolean
C1960398 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
Neoplasm Metastasis | Status post First line treatment | Recurrent disease Post Neoadjuvant Therapy | Recurrent disease Post Adjuvant therapy | Herceptin | Taxanes
Item
metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with herceptin and taxanes
boolean
C0027627 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0277556 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C0600558 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
C0677850 (UMLS CUI [4,3])
C0338204 (UMLS CUI [5])
C0796419 (UMLS CUI [6])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases Poorly controlled
Item
cns metastases which are not well controlled
boolean
C0686377 (UMLS CUI [1,1])
C3853134 (UMLS CUI [1,2])
sorivudine
Item
simultaneous treatment with sorivudine
boolean
C0207628 (UMLS CUI [1])
Cancer Other | Exception Basal cell carcinoma Cured | Exception Carcinoma in situ of uterine cervix Cured
Item
history of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial